@RheumNow hard at work, shooting KOL videos, at #EULAR2023 https://t.co/C9n2218oeU

ANSWER cohort Retrospective study 6600+ bio/tsDMARDs ttmt courses, 20 yrs ✔️IL-6Ri is the lowest discontinued for lack of efficacy ✔️CTLA4-Ig is the lowest discontinued due to AEs ✔️Concomitant GC ⬆️30% drug discontinuation due to AEs @Rheumnow #EULAR23 POS0051 https://t.co/8e6U5KHmX4

The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8) Use of TNFi & orthopedic implants associated w/ OAI risk Mortality however similar in RA and non RA groups @RheumNow #EULAR23 POS0033 https://t.co/H6JYkbNu0B

Always great to have @EMA_News to come and to talk to us at #EULAR2023 Our meds are very important to us, and the more we can understand how decisions are made and RWE is collected, the better 👍 @RheumNow https://t.co/hSutraUsFD

#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results @RheumNow https://t.co/UoZ2xS3IzC

NYU's star rheumatologist, Dr. Jose Scher, wit on the fly at #EULAR2023 https://t.co/O9afiVHSV5

Can combined US examination of nail-enthesis complex & nailfold videocapillaroscopy differentiate PsA from PSO RA and HC? Brief answer is no, but: -PsA > tortuous capillaries vs. PSO & HC -Abnormalities in PSO to be used as predictor of PsA? TBC... @RheumNow #EULAR23 POS0025 https://t.co/RNbpht8QGh

#EULAR2023 #POS1147 Primary endpoint for Cenerimod (S1P1 modulator) phase 2 RCT in #SLE was not met after multiple testing. Post-hoc analysis showed greater reduction in SRI-4 and mSLEDAI in IFN-High vs IFN-Low at 6mths. A biomarker to stratify response in Phase 3 @RheumNow https://t.co/wKM5V1JgXT

Fluorescence optical imaging in early arthritis? Nice images but not ready for clinics yet Can not differentiate OA from RA & PsA SLE/SSc associated arthritis display a specific pattern, but usually auto-antibody profiles help w/ diagnosis OP0173 #EULAR23 @Rheunow https://t.co/bAMi9kDKS5

Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/TDKWxgrST0

Professor Ingrid Lundberg reviews the co associations amongst the inflammatory myopathies #EULAR2023 https://t.co/B9Idyz90Lh